- Home
- NGNE vs HFRO Comparison
NGNE vs HFRO Comparison
Compare NGNE & HFRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- HFRO
- Stock Information
- Founded
- NGNE 2003
- HFRO 2000
- Country
- NGNE United States
- HFRO United States
- Employees
- NGNE N/A
- HFRO N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- HFRO Finance/Investors Services
- Sector
- NGNE Health Care
- HFRO Finance
- Exchange
- NGNE Nasdaq
- HFRO Nasdaq
- Market Cap
- NGNE 325.3M
- HFRO 287.7M
- IPO Year
- NGNE N/A
- HFRO N/A
- Fundamental
- Price
- NGNE $20.51
- HFRO $6.02
- Analyst Decision
- NGNE Strong Buy
- HFRO
- Analyst Count
- NGNE 7
- HFRO 0
- Target Price
- NGNE $41.86
- HFRO N/A
- AVG Volume (30 Days)
- NGNE 123.0K
- HFRO 179.8K
- Earning Date
- NGNE 08-11-2025
- HFRO 01-01-0001
- Dividend Yield
- NGNE N/A
- HFRO 8.87%
- EPS Growth
- NGNE N/A
- HFRO N/A
- EPS
- NGNE N/A
- HFRO N/A
- Revenue
- NGNE N/A
- HFRO N/A
- Revenue This Year
- NGNE N/A
- HFRO N/A
- Revenue Next Year
- NGNE N/A
- HFRO N/A
- P/E Ratio
- NGNE N/A
- HFRO N/A
- Revenue Growth
- NGNE N/A
- HFRO N/A
- 52 Week Low
- NGNE $6.88
- HFRO $4.24
- 52 Week High
- NGNE $74.49
- HFRO $6.45
- Technical
- Relative Strength Index (RSI)
- NGNE 47.72
- HFRO 79.30
- Support Level
- NGNE $18.94
- HFRO $5.19
- Resistance Level
- NGNE $21.59
- HFRO $6.04
- Average True Range (ATR)
- NGNE 1.40
- HFRO 0.11
- MACD
- NGNE -0.26
- HFRO 0.05
- Stochastic Oscillator
- NGNE 32.30
- HFRO 97.06
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.